Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score–matched analysis of E7438-G000-101 trial outcomes

DG Proudman, D Gupta, D Nellesen, J Yang… - …, 2022 - pmc.ncbi.nlm.nih.gov
DG Proudman, D Gupta, D Nellesen, J Yang, BA Kamp, K Mamlouk, BD Cheson
Oncotarget, 2022pmc.ncbi.nlm.nih.gov
Purpose: In the tazemetostat E7438-G000-101 trial of relapsed/refractory (R/R) follicular
lymphoma (FL), apparent superior efficacy was suggested for mutant-type (MT) EZH2 versus
wild-type (WT) status. However, clinical disparities might have contributed to this conclusion.
This study aimed to estimate outcomes after minimizing differences in baseline
characteristics. Methods: Propensity scores for each participant with WT (n= 54) and MT (n=
45) status were generated based on the likelihood of being selected given their baseline …
Purpose
In the tazemetostat E7438-G000-101 trial of relapsed/refractory (R/R) follicular lymphoma (FL), apparent superior efficacy was suggested for mutant-type (MT) EZH2 versus wild-type (WT) status. However, clinical disparities might have contributed to this conclusion. This study aimed to estimate outcomes after minimizing differences in baseline characteristics.
Methods
Propensity scores for each participant with WT (n = 54) and MT (n = 45) status were generated based on the likelihood of being selected given their baseline characteristics. Participants were matched using a 1:1 nearest-neighbor approach.
Results
The propensity-matched sample included 56 participants (28 WT, 28 MT). Objective response rates (95% confidence interval [CI]) were 35% (22–48) in WT and 69% (55–83) in MT prior to matching and 50% (31–69) in WT and 71% (54–88) in MT after matching. Median progression-free survival values (95% CI) were 11.1 (5.4–16.7) in WT and 13.8 months (11.1–22.1) in MT prior to matching and 14.3 (11.1–∞]) and 14.8 months (10.7–∞]) in WT and MT matched groups, respectively.
Conclusions
This analysis suggests that efficacy outcomes for tazemetostat observed in participants with WT EZH2 R/R FL may have been similar to those in participants with MT had the 2 cohorts been more closely matched.
pmc.ncbi.nlm.nih.gov